Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium bifidum CBT-BF3
- Development stage
- Unknown
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum CBT-BF3 is a specific probiotic bacterial strain developed by Cell Biotech Co., Ltd. Originally isolated from cheese and deposited under accession number KCTC 12199BP, this live biotherapeutic agent is designed to modulate the gut-skin axis and the systemic immune response. Its mechanism involves the promotion of beneficial gut microbiota (such as other Bifidobacterium and Bacteroides species) while inhibiting pathogenic bacteria like Escherichia and Shigella. Immunologically, it has been shown to induce T-cell differentiation toward Treg and Th1 phenotypes while suppressing Th2 activity, making it a candidate for the treatment of atopic dermatitis and the promotion of infant growth and gut health. It is typically administered as a freeze-dried powder and has been evaluated as a Generally Recognized as Safe (GRAS) substance by the FDA for food applications.
- Other names
- Bifidobacterium bifidum CBT-BF3KCTC 12199BPKCTC12199BPKCTC-12199BPKCTC12201BPKCTC-12201BPKCTC 12201BP
Beyond the preview
Go deeper on Bifidobacterium bifidum CBT-BF3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium bifidum CBT-BF3.